SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement (the “Agreement”) to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, August 4, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) is pleased to announce that its common shares were accepted for listing on the Frankfurt Stock Exchange (“FSE”) under the trading symbol…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, July 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that block replication of SARS-CoV-2, the coronavirus that causes COVID-19. In a cell-based…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, July 9, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the appointment of Dr. H. Michael Shepard to its Board of Directors. Dr. Shepard was a 2019 recipient…
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA, May 27, 2020 – Pascal Biosciences Inc. (TSX.V: PAS) ("Pascal") entered into a non-binding term sheet with SōRSE Technology Corporation ("SōRSE")…
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V: PAS) ("Pascal") is pleased to announce that it has entered into a…
Read MoreThe project will utilize Pascal’s proprietary antibodies & Y-Biologics’ novel bispecific antibody platform technology, ALiCE Vancouver, British Columbia, Seattle, Washington and Daejon, Korea, Oct. 29, 2019 — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today announced…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 23, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment. Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumor…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 11, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”). Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 29, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the company will present at the upcoming BIO International Convention taking place June 3-6…
Read More